IBA and Elektra initiate global particle therapy program

5 November 2007

Belgium's Ion Beam Applications SA and Swedish firm Elekta AB have announced a global particle therapy collaboration program to optimize the seamless integration of proton therapy delivery and information management systems within the radiation oncology environment. Both companies are currently showcasing their products at the 49th Annual Meeting of the American Society for Therapeutic Radiology and Oncology being held in Los Angeles, USA, from October 28 to November 1.

The aim of this deal is to offer fully-integrated, open and comprehensive cancer treatment solutions to the particle therapy market. Both companies have unique competence in their respective fields of radiation therapy and have decided to join forces to simplify the integration of the many components that are necessary in an advanced proton therapy center.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight